Liquid Biopsy Market is Expected to Reach USD 7.1 Billion by 2027

Liquid biopsy market is forecasted to grow at high rate due to an increasesing number of detection technologies, clinical studies, and high prevalence of numerous cancers.The Global Liquid Biopsy Market size was valued at USD 2.4 Bn in 2020 expected to reach USD 7.1 Bn by 2027, with a growing CAGR of 19.9% during the forecast period

Liquid biopsy is an isolation of DNA fragments from the blood associated with the tumor cells for the detection of genetic abnormalities. The increasing volume of tumorous cells lead to large number of phagocytes to discard the dead cells apoptotic, leading to an increase in the cell fragments in the blood stream. These fragments contain the DNA which help in detecting the genetic alterations. The application of liquid biopsy has grown due to monitoring of instruction in surgeries to diagnostic profiling of genome. The liquid biopsy is beneficial to detect the tumor and cancerous cells at an early stage.

With the tremendous rise in various genetic and molecular disorders, the number of liquid biopsy is increasing and getting importance in health sciences. Awareness of various genetic and molecular disorders and their detection are expected to lubricate the growth of liquid biopsy market.

Moreover, an increase in the prevalence of tumors, human genetic variations, breast cancers, and genetic disabilities and its treatments are expected to attract more customers and enhance the growth of liquid biopsy market during the forecast period. Liquid biopsy is used in the detection of disorders to avoid the abnormalities in the genome and detect the cancer to avoid the severity with an early detection.  

The global liquid biopsy market is broadly segmented into sample type, application, biomarker technology end-user and region. Sample type is segregated into blood sample, urine sample and other bio fluids (tissue fluids and saliva). Based on sample type, blood sample segment has gained tremendous market shares in 2020 and expected to gain more during forecast period. This is due to an increase in the rate of diagnosis, detection of various genetic disorders, and interpretation to start the early treatment support the growth of liquid biopsy industry in this segment.

Application is further bifurcated into therapy selection for metastatic breast cancer (MBS), therapy selection for other metastatic cancer and molecular health monitoring services. Based on application, therapy selection for metastatic breast cancer (MBS) segment is expected to show maximum growth in market shares for 2020, expecting more growth during the forecast period. This is due to an increasing usage of advanced techniques for the diagnosis purpose. These technologies are specialized for multiple uses such as whole genome sequencing, target genome sequencing, and many others for the prenatal testing.

The technology is divided into multi-gene-parallel analysis (NGS) and single gene analysis (PCR Microarrays). Based on technology, the multi-gene-parallel analysis (NGS) segment has gained tremendous market shares in 2020 and expected to gain more during forecast period. According to WHO-World health organization, lung cancer is the most common type of cancer leading to death, an estimate of about 1.80 million deaths have occurred. Thus, the high prevalence of cancer detection and its diagnosis are expected to drive the segment in the market.

Global Liquid Biopsy Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on region, North America dominated the liquid biopsy market in 2020 and is expected to maintain the same dominance throughout the forecast period. The rising prevalence of numerous cancers, advanced healthcare infrastructure, increase in rapid detection and screening technologies, increasing incidence of various tumor conditions in the population drives the growth of the market in this region.

The Global Liquid Biopsy Market Segmentation:

Global Liquid Biopsy Market by Sample Type Outlook (Revenue, USD Million, 2021-2027)

• Blood Sample
• Urine Sample
• Other Bio Fluids (Tissue fluids and Saliva)

Global Liquid Biopsy Market by Application Outlook (Revenue, USD Million, 2021-2027)

• Therapy Selection for Metastatic Breast Cancer (MBS)
• Therapy Selection for Other Metastatic Cancer
• Molecular Health Monitoring Services

Global Liquid Biopsy Market by Biomarker Outlook (Revenue, USD Million, 2021-2027)

• Circulating Tumour Cells (CTC)
• Circulating Tumour DNA (ctDNA)
• Exosomes

Global Liquid Biopsy Market by Technology Outlook (Revenue, USD Million, 2021-2027)

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Global Liquid Biopsy Market by End-user Outlook (Revenue, USD Million, 2021-2027)

• Hospitals
• Diagnostic Laboratories
• Others (Research Institutes)

Key Findings:

• Based on sample type, the blood sample segment accounted for the largest share of the market in 2020 and is expected to gain more during the forecast period.
• Based on application, therapy selection for metastatic breast cancer (MBS) segment is expected to observe maximum growth in market shares (2020) and is expected to gain more witness more during the forecast period.
• Based on biomarker, the circulating tumour DNA (ctDNA) segment has gained a tremendous market share in 2020.
• Based on technology, the multi-gene-parallel analysis (NGS) segment held maximum share in 2020 and expected to maintain its dominance during the forecast period.
• Based on end-user, the diagnostic laboratories segment has gained tremendous market shares in 2020 and expected to gain more during the forecast period.

Company Profiles and Competitive Intelligence

The key players operating in the market are:

• Biocept, Inc.
• MDxHealth
• Myriad Genetics, Inc.
• Bio-Rad Laboratories
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Genomic Health, Inc.
• Illumina, Inc.
• Vermillion, Inc.
• Foundation Medicine, Inc.
• OncoCyte Corporation
• Veracyte, Inc, Inc.
• Guardant Health, Inc.
• NeoGenomics Laboratories, Inc.
• Personal Genome Diagnostics, Inc.
• RainDance Technologies, Inc.
• Trovagene Inc.
• Adaptive Biotechnologies.
• Cynvenio Biosystems, Inc.

Recent News:

1. In November 2020, the Food and Drug Administration (FDA) enlarged and approved the uses for a blood test called as liquid biopsy. The test interprets the changes in the DNA of the tumor cells.
2. In January 2021, the U.S FDA approved a new test for the detection of circulating DNA in the blood from the cancerous tumors. The tests interpret the severity of the disease through genetic material of the tumor cells.